TrialClinical and translational science2023

A first-in-human phase I study of SHR-1906, a humanized monoclonal antibody against connective tissue growth factor, in healthy participants.

Lin-Lin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.